HealthMyne, Inc. and Moffitt Cancer Center Sign Imaging Analytics Technology Agreement

MADISON, WISCONSIN (October 6, 2015) – HealthMyne, Inc., a clinical imaging informatics company, has agreed to a research and product evaluation agreement with Moffitt Cancer Center. The primary objective of the agreement is the implementation of an imaging analytics software platform, with an initial focus on thoracic oncology.

“We are very excited to reach this important milestone with Moffitt.  Their investigators are global leaders in oncology research and care and are pioneering the exciting new field of radiomics,” stated Praveen Sinha, HealthMyne CEO.  “Quantitative imaging analysis and patient cohort comparisons can effectively and efficiently offer REAL big data benefits to both researchers and clinical care team members alike.”

One important component of the technology agreement is a structured, mineable repository of de-identified tumor descriptors that will allow investigators to evaluate samples for imaging biomarkers.  “The tumor characterization and data mining capabilities that the HealthMyne solution provides will help to accelerate our efforts to identify and validate important radiomic signatures,” said to Robert J. Gillies, PhD, chair of the Department of Cancer Imaging and Metabolism at Moffitt.  “We have moved from viewing images as pictures to seeing them as data, and that is a very empowering clinical care step.”

About HealthMyne, Inc.
HealthMyne, Inc. is a healthcare IT company that brings evidence-based imaging analysis and
actionable insights to radiologists and oncologists at the point of care. The company’s unique approach to clinical imaging enables healthcare providers to optimize individual patient care, while lowering overall care cost. The company was founded in 2013 by a seasoned group of highly successful healthcare industry entrepreneurs. For more information, visit healthmyne.com.
 

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.